TrialThe New England journal of medicine2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Michael L Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
802 papers cite itlatest 60 shown
this paperpooled ittrialcites it